The Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) and features dormant and discontinued products.
GlobalData tracks five drugs in development for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) by five companies/universities/institutes. The top development phase for Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) is phase i with two drugs in that stage. The Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline products market are: Jazz Pharmaceuticals, Celixir and Anviron.
The key targets in the Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline products market include Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1).
The key mechanisms of action in the Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline product include Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Inhibitor with one drug in Phase II. The Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) pipeline products market including Small Molecule, and Cell Therapy.
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) overview
Kawasaki disease, or mucocutaneous lymph node syndrome, is a rare illness that mainly affects children under the age of 5. Symptoms include swollen glands in the neck; dry, red cracked lips; strawberry tongue; and swelling of the mucous membranes inside the mouth, nose, eyes, and throat. Diagnostic criteria include prolonged fever for more than five days and generally higher than 101.3 F, and four out of the following five findings: Bilateral conjunctival injection, oral changes such as cracked and erythematous lips and strawberry tongue, cervical lymphadenopathy, and extremity changes such as erythema. Diagnostic tools include urine tests, blood tests, and cerebrospinal fluid examination. Treatment for Kawasaki disease includes intravenous gamma globulin (IVIG), high-dose aspirin every six hours, and low-dose aspirin for at least six weeks after the fever goes down.
For a complete picture of Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
